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Can immune reprogramming with
alemtuzumab induce permanent remission
in multiple sclerosis?
Disease-modifying therapies (DMTs) for multiple
sclerosis (MS) have developed tremendously over
the last 2 decades. Currently, more than 16 different
products targeting various immunologic components
have been approved for MS treatment in several
countries.
The high number of MS treatments has made the
management of patients increasingly complex. Two
main therapeutic strategies are currently adopted in
the clinical setting: (1) escalation (or optimization)
therapy or (2) induction (or immune reset) therapy
(figure). In the escalation/optimization strategy,
alemtuzumab is recommended as a second- or
third-line therapy to patients who have had an inad-
equate response to initial DMTs. In the induction
strategy, it has instead been argued by some investi-
gators that alemtuzumab should be used as a first-line
agent with the intention of inducing long-term dis-
ease stability. However, long-term follow-up studies
are needed to know what percentage of patients have
a durable response to alemtuzumab without the
development of severe side effects.
Alemtuzumab is an immune-depleting therapy
that has 3 major parts to its mechanism of action:
(1) selective targeting of CD52 on T and B cells,
and to a lesser extent, innate immune cells; (2) imme-
diate depletion of immune cells; and (3) perhaps the
most important and least understood part, a phase of
immune cell repopulation. Depletion of CD521
immune cells occurs mainly in the periphery and sub-
sequent effects are translated to the CNS.1 Investiga-
tion of the long-term effects of alemtuzumab on
various subtypes of immune cells, such as T effector
memory and resident memory T cells, illustrates as-
pects of repopulation and immune reprogramming.2
The drug administration route and dosing, the per-
sistently low CD4 and CD8 T-helper cell levels, and
the occurrence of secondary autoimmunity during
the phase of immune cell repopulation suggest that
alemtuzumab induces a reprogrammed immune rep-
ertoire. Alemtuzumab thus might produce a durable
therapeutic response as a consequence of a permanent
rebalancing of the immune system.
In this issue of Neurology®, Havrdova et al.3 and
Coles et al.4 report efficacy and safety results of 3-
year extension studies of both Comparison of Alem-
tuzumab and Rebif Efficacy in Multiple Sclerosis I
and II (CARE-MS I and II) trials. These were 2-
year, phase III, randomized, active-controlled trials
that compared alemtuzumab with interferon-b-1a
in patients with relapsing-remitting MS and active
disease (defined as $2 relapses in the last 2 years
and $1 relapse in the last year). The main differ-
ence between the 2 trials is that CARE-MS I pa-
tients had never received disease-modifying
treatment, while CARE-MS II patients had relapsed
after prior treatment with other therapies. In both,
treatment with alemtuzumab consisted of 5 daily 12
mg infusions at the start of therapy, and another
round occurring 1 year later consisting of 3 daily
12 mg infusions. Analysis of the extension studies
showed that the annualized relapse rate at 5 years
was 0.15 in CARE-MS I and 0.18 in CARE-MS II.
The cumulative fraction of participants with no
evidence of clinical and MRI disease activity over
years 3–5, referred to as no evidence of disease
activity (NEDA), was 39.5% in CARE-MS I and
27% in CARE-MS II. Importantly, 67.3% and
55.5% of participants enrolled into the extension
studies did not require any DMT over 3 years after
the second alemtuzumab treatment, and it can be
argued that they were experiencing a drug-
treatment-free remission (figure); the remaining
32.7% and 44.5% of patients received treatment
with alemtuzumab or another DMT. A total of
33% and 42.9% of patients showed a confirmed
disability improvement (defined as $1-point
Expanded Disability Status Scale decrease from
a baseline score $2.0) over 5 years. The median
yearly brain parenchymal fraction change was
20.2 in the extension of CARE-MS I and 20.07
in the extension of CARE-MS II.
These efficacy results must be considered with
some caution, however, considering that there are
biases typical of extension studies with open-label de-
signs, including the lack of blinding and the lack of
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a control group. In addition, 4.9% of CARE-MS I
patients and 7.1% of CARE-MS II patients declined
to be enrolled in the extension studies; while this is an
unusually high enrollment rate for an extension
study, these percentages should be kept in mind
and perhaps subtracted from the reported rates of
NEDA and percentage of patients who did not
require treatment with a DMT over the 3 years after
alemtuzumab treatment. Since the decision to con-
tinue treatment with alemtuzumab or any other drug
was left to the treating physicians and patients, pa-
tients may have remained untreated despite disease
progression (which was permissible in the extension
study), and the opinions of nonblinded investigators
could have influenced the detection of disease
activity.
Figure Overview of therapeutic concepts in multiple sclerosis: Chronic vs induction therapies
(A) Chronic therapy strategies requiring the continuous application of treatments over time, with a possibility for optimiza-
tion/escalation of treatment. (B) Induction therapies are applied with less frequent and more disease pathogenesis interven-
ing doses that are followed by a no continuation therapy (a), repeated induction treatments on a regular or as-needed basis
(b), or maintenance therapy with maintenance treatment (c).
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Extension studies are undoubtedly useful in
improving our knowledge of side effects of new med-
ications. This is especially relevant for alemtuzumab,
whose key adverse events include infusion reactions,
immune-mediated thyroid disease, immune throm-
bocytopenia (ITP), and glomerulonephritis. Alemtu-
zumab may also be associated with other serious
complications, as suggested by recent cases of Listeri-
osis monocytogenes, cytomegalovirus syndrome, pul-
monary and CNS nocardiosis, and B-cell-mediated
CNS disease.5–7 Both extension studies reported
new findings in respect to the core studies, which
included a substantial risk of herpes zoster reactivation,
with 25 new cases in the extension of CARE-MS I and
35 cases in the extension of CARE-MS II, and a rela-
tively high 5-year incidence of thyroid autoimmunity
(40.7% and 37.7%, respectively). Particular attention
should be given to papillary thyroid carcinoma, with 1
new case in the extension of CARE-MS I and 2 new
cases in the extension of CARE-MS II. Eleven new
cases of ITP occurred overall in the extension studies
and 1 case of nephropathy was seen at year 3 in the
extension of the CARE-MS I trial. Whether additional
serious adverse events will develop beyond 3 years after
the last infusion of alemtuzumab remains to be
determined.
Overall, the extension studies of CARE-MS I and
CARE-MS II trials suggest that therapy-free remis-
sion can be achieved in over 50% of patients follow-
ing 2 courses of alemtuzumab, indicating that
a sustained immunologic reprogramming of the dis-
turbed immune repertoire can be achieved in many
patients. Further follow-up is needed to determine
how long this immunologic reprogramming will last.
Several challenges remain in the use of alemtuzumab.
These include the need to identify prognostic bio-
markers that identify patients who are more likely
to benefit from an induction treatment strategy and
the need for longer observation periods to confirm
the safety profile of alemtuzumab, which is crucial
in selecting this drug over another highly efficacious
therapy, natalizumab.8 An interesting question that,
if addressed, may shed some light into the pathogen-
esis of MS is why some patients show disease wors-
ening despite immune-depleting therapy.
The possibility of inducing a long-term or even per-
manent drug-free remission in people with relapsing-
remitting MS with alemtuzumab is exciting and novel
in MS therapy. The challenge is to define which pa-
tients warrant treatment with this potent therapy and
identifying ways to mitigate serious side effects.
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